<DOC>
	<DOCNO>NCT01285180</DOCNO>
	<brief_summary>Daxas ( roflumilast ) first oral anti-inflammatory phosphodiesterase inhibitor ( PDE-4 ) patient severe chronic obstructive pulmonary disease ( COPD ) experience chronic cough sputum history exacerbation add-on bronchodilator treatment . With mode action Daxas reduce exacerbation rate improve lung function parameter may result good health-related quality life improve long-term management COPD . The aim non-interventional study evaluate data quality life COPD patient Germany real life medical setting . Evaluation base two COPD specific questionnaire assess patient ` health status six month . During study , socio-demographic data cost-of-illness data record . Daxas ( tablet ) administer daily . The study provide data safety tolerability Daxas .</brief_summary>
	<brief_title>Quality Life Daxas-treated Patients Older Than 18 Years With Severe COPD</brief_title>
	<detailed_description />
	<criteria>Main severe COPD Main Child pugh ( classified B C )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Quality life</keyword>
	<keyword>sociodemographic data</keyword>
	<keyword>cost-of-illness data</keyword>
	<keyword>roflumilast</keyword>
	<keyword>Daxas</keyword>
</DOC>